Pacira BioSciences Inc. (PCRX)
PCRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1396814/000162828026012297/0001628280-26-012297-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PCRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2011 |
| SEC CIK | 0001396814 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $726.4M |
| Net income | $7.0M |
| Operating income | $19.2M |
| Net margin | 1.0% |
| Operating margin | 2.6% |
| Revenue growth | +3.6% |
| Cash | $158.5M |
| Total assets | $1.3B |
| P/E (computed) | 207.9× |
| P/S (computed) | 2.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $247.0M cash; operating cash flow $44.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 40,094,660 (2026-11-04); 43,021,275 a year earlier; 46,437,704 three years earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Short Hills, New Jersey, United States | PCAOB Form AP 2026-03-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $2.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $176.7M | $28.5M | $50.1M | $247.0M | $293.6M | $743.3M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $192.4M | $4.7M | $57.5M | $205.9M | $363.1M | $746.2M | 10-Q 2026-08-04 |
| Q1 2026 2026-03-31 | $177.4M | $2.9M | $25.7M | $144.3M | $367.7M | $734.9M | 10-Q 2026-04-30 |
| Q4 2025 2025-12-31 | $196.9M | $1.6M | $43.7M | $158.5M | $372.2M | $726.4M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $179.5M | $5.4M | $60.8M | $147.6M | $376.7M | $716.8M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $181.1M | -$4.8M | $12.0M | $300.5M | $580.5M | $705.8M | 10-Q 2026-08-04 |
| Q1 2025 2025-03-31 | $168.9M | $4.8M | $35.5M | $283.6M | $583.4M | $702.8M | 10-Q 2026-04-30 |
| Q4 2024 2024-12-31 | $187.3M | $16.0M | $33.1M | $276.8M | $585.3M | $701.0M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2014-04-09 |
| Latest annual report 10-K - PCRX - 12.31.2025 | 10-K | 2026-02-26 |
| Latest quarterly / interim 10-Q - PCRX - 9.30.2026 | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-06-04 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.1% |
| 1 month | +0.4% |
| 3 months | +57.3% |
| Year to date | +40.9% |
| 1 year | +54.4% |
| From 52-week high | -0.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RAPP | Rapport Therapeutics Inc. | $24.82 | -5.09% | $1.5B |
| NBTX | Nanobiotix S.A. | $28.54 | -6.90% | $1.5B |
| KRSA | Korsana Biosciences Inc. | $32.68 | +3.25% | $1.5B |
| PAHC | Phibro Animal Health Corporation | $35.02 | -2.64% | $1.4B |
| SLS | SELLAS Life Sciences Group Inc. | $7.47 | -4.96% | $1.5B |
| QURE | uniQure N.V. | $21.88 | -8.11% | $1.5B |
| DMRA | Damora Therapeutics Inc. | $22.50 | +4.14% | $1.4B |
| LBRX | LB Pharmaceuticals Inc | $42.99 | -0.05% | $1.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier